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Abstract 
Radiometals are becoming increasingly accessible and are utilized frequently in the design of 
radiotracers for imaging and therapy. Nuclear properties ranging from the emission of g-ray and 
b+-particles (imaging) to Auger electron, b- and a-particles (therapy) in combination with long 
half-lives are ideally matched with the relatively long biological half-life of monoclonal antibodies 
in vivo. Radiometal labelling of antibodies requires the incorporation of a metal chelate onto the 
monoclonal antibody. This chelate must coordinate the metal under mild conditions required for 
the handling of antibodies, as well as provide high kinetic, thermodynamic and metabolic stability 
once the metal ion is coordinated in order to prevent in vivo release of the radionuclide before the 
target site is reached. Herein, we review the role of different radiometals that have found 
applications the design of radiolabelled antibodies for imaging and radioimmunotherapy. Each 
radionuclide is described with regard to its nuclear synthesis, coordinative preference, and 
radiolabelling properties with commonly used chelates. A summary of recent developments in the 
area of chelate synthesis, as well as examples of their preclinical and clinical applications is 
presented. The aims of review are to provide an overview of recent trends in antibody-based 
radiopharmaceuticals and to spur continued development of the chemistry and application of 
radiometals for imaging and therapy. 
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Introduction 
In the pharmaceutical industry, biological products (biologics) and related biosimilar compounds 
represent one of the fastest growth sectors. In 2016, the size of the biologics market was estimated 
to be ~$200 billion USD. Recent forecasts predict continued growth at around 10% per annum 
with the market reaching ~$480 billion USD by 2024. Biologics include recombinant hormones 
and proteins, as well as cellular- and gene-based therapies, but the majority of this growth is driven 
by new vaccines and monoclonal antibodies (mAbs). Monoclonal antibodies or antibody-drug 
conjugates (ADCs) represent the single most important branch of biologics.1 Between 2011 and 
August 2017, the United States Federal Drug Administration (US-FDA) approved a total of 235 
New Molecular Entities (NMEs), of which 37 were either mAbs or ADCs for therapy (Figure 1). 
This growing trend is supported by historical data which suggest that biologics, and mAbs in 
particular, have received higher approval rates than conventional small-molecule drugs.2 With 
prescription costs for mAb-based treatments estimated to be around 22-times more than small-
molecule therapies, and profit margins often over 40%, it is easy to see the commercial attraction 
of biologics. However, this success is partially offset by the longer time frames required from 
initial clinical trials to full approval, more stringent manufacturing regulations, and the associated 
increase in costs. Recent changes to US legislation, implemented as part of the Patient Protection 
and Affordable Care Act of 2010, are also helping to create an abbreviated licensure pathway for 
NMEs that are demonstrated to be “biosimilar” to, or “interchangeable” with, an FDA-licensed 
biological product. This new legal framework will speed-up the discovery and clinical translation 
of mAb-based agents. 
 In nuclear medicine, desirable biochemical properties including high target affinity, 
specificity and selectivity, pre-optimised pharmacokinetics, and relative ease of selection using 
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various library technologies mean that antibody-based radiotracers are attractive platforms for 
developing diagnostic imaging and radioimmunotherapy (RIT) agents.3–6 Nevertheless, production 
and validation of radiolabelled mAbs for use as immuno-single photon emission computed 
tomography (immuno-SPECT), immuno-positron emission tomography (immuno-PET) or RIT 
agents is non-trivial.3 Synthesis of radiolabelled mAbs requires chemical reactions on the protein 
(Figure 2). Functionalisation usually involves post-translational modification of amino-acid side 
chains (particularly peptide bond formation using the primary amine group of lysine residues), 
derivatisation of cysteine sulfhydryl groups, or site-specific labelling of glycans using chemical 
and/or enzymatic methods.7,8 More recent protein engineering routes have also exploited site-
specific enzymatic ligation with prominent methods including transglutaminase derivatisation, 
sortase coupling and formylglycine reactions to produce a range of ADCs.7–9 While the chemical 
nature of the linker group plays an important role in determining the metabolic stability and 
pharmacokinetics of a radiolabelled mAb, an equally important decision revolves around the 
choice of the radiometal ion and the chelation chemistry used to produce thermodynamically and 
kinetically stable radiometal ion complexes.10 In this review, we discuss the chemical requirements 
for chelation of various radiometal ions and highlight selected applications of radiometal chemistry 
in the development of radiotracers for immuno-PET, immune-SPECT and RIT.11  
 
1. Radionuclides for antibody imaging and therapy 
 In this issue of the Journal of Labelled Compounds and Radiopharmaceuticals, Engle and co-
workers present an overview of the emerging radionuclides for use in combination with mAbs for 
diagnostic and RIT applications. Pertinent physical decay characteristics of 11 radiometal ions, 
and for comparison three different iodine radionuclides are presented in Table 1.12 When selecting 
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a radionuclide for labelling antibodies or antibody-related constructs, the most crucial decision is 
to ensure that the physical half-life of the radionuclide is a reasonable match to the expected 
biological half-life of the radiotracer in vivo.10 For example, 68Ga (t1/2 = 67.7 min.) is an excellent 
radionuclide for producing PET radiotracers based on small-molecules and peptides but would be 
an inappropriate choice for developing immuno-PET radiotracers based on full-sized mAbs 
(molecular weight ~150 kDa). Experience has found that mAbs reach optimum target (usually 
tumour) uptake and present maximal tumour-to-background contrast ratios in mouse models at 
around 24 – 96 h post-administration. Hence, in this pharmacokinetic situation, 68Ga is likely to 
undergo complete decay before the biodistribution of a radiolabelled mAb reaches the optimum 
imaging window. Notably, in humans the pharmacokinetic profiles of radiolabelled mAbs are 
often slower than in rodents, with optimum target accumulation and image contrast achieved at 
time points beyond 72 h post-administration of the radiotracer. Such prolonged circulation times 
necessitate the use of radionuclides that have physical half-lives ranging from ca. 10 hours to 
several days. For immuno-PET imaging, 64Cu, 86Y, 89Zr and 124I are the most commonly used 
radionuclides, whereas for immuno-SPECT, 67Ga, 99mTc, 111In, 123I and 177Lu have been the 
radionuclides of choice. The majority of radiolabelled mAbs for applications in RIT use the beta-
emitting radionuclides 90Y, 131I, and 177Lu. Other radionuclides of note for potential RIT 
applications include the dual-decay mode of 64Cu (branching ratio of 38.5% beta-decay to the 
daughter nuclide 65Zn), 67Cu13 and the alpha emitter 225Ac.14,15 
 
2. Copper radiolabelled antibodies 
Copper has a range of radionuclides with varying decay characteristics that are suitable for 
applications in both nuclear imaging and molecularly targeted radionuclide therapy.16 PET 
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imaging radionuclides of copper include 60Cu (t1/2 = 23.7 min.), 61Cu (t1/2 = 3.333 h), 62Cu (t1/2 = 
9.67 min.) but with the possible exception of 61Cu for use in radiolabelling small peptides, proteins 
and antibody-based fragments, the most suitable radionuclide for combination with immuno-PET 
is 64Cu.17 In addition to PET imaging, 64Cu also shows potential for therapeutic applications via 
separate decay involving beta-particle emission. However, 67Cu (t1/2 = 61.83 h; b– = 100%) with 
a maximum linear energy transfer of 561.7 keV is one of the most promising radionuclides for 
potential development of 67Cu-mAbs for RIT.18 
 While the radiochemical landscape of copper radionuclides presents opportunities for 
developing imaging and therapeutic agents, controlling the chemistry of copper ions in vivo 
remains a formidable challenge.19,20 Copper chemistry in oxygenated, aqueous conditions is 
dominated by the Cu2+ cation. Cu2+ ions have a d9 electronic configuration which induces large 
Jahn-Teller distortion in the first coordination sphere and the additional crystal field stabilisation 
favours complexes with a 4-coorindate, square planar geometry. The charge density of Cu2+(aq.) 
ions (ionic radius = 0.80 Å)21  lies intermediate between hard class A ions and softer class B metal 
ions. This property means that Cu2+ ions favour coordination with chelating ligands that present a 
mixed donor set with both small, hard donors like N and O, and larger, soft S donors. For this 
reason, some of the most successful chelates for coordinating Cu2+ ions have been developed 
around bis-thiosemicarbazonato-based ligand systems that offer dative covalent bond formation 
via N2S2 or N2SO donor atoms sets (Figure 3).22 Although tetra-coordinate, square planar 
complexes with a fully occupied d(z2)2 orbital stabilise Cu2+ ions thermodynamically, ligands like 
H2ATSM, and the asymmetric bifunctional version H2ATSM/A, have two faces of the central 
metal cation open to solvent.23 Solvent exposed sites in the first coordination sphere leave 
complexes like CuATSM susceptible to degradation via nucleophilic attack, which can decrease 
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their overall kinetic/metabolic stability in vivo. In the case of copper-based radiotracers, loss of the 
metal ion from the radiopharmaceutical leads to higher accumulation of radioactivity in 
background tissues such as the liver, spleen and kidneys. For immuno-PET and immuno-SPECT 
agents, such instability can complicate analysis and quantification by reducing target specificity 
and decreasing image contrast. For RIT, off-target accumulation of radioactivity causes a potential 
problem in terms of dosimetry with the need to avoid radiation dose to background organs to 
minimise potential side-effects. Therefore, when developing copper-based mAbs, it is of 
paramount importance to minimise demetallation/transchelation in vivo.  
 Another aspect of copper chemistry that must be taken into account when selecting a suitable 
ligand is the fact that Cu2+ ions undergo facile one-electron reduction to their corresponding Cu+ 
species. While square planar Cu2+ complexes are thermodynamically stable due to high crystal 
field splitting forces, Cu+ complexes prefer a tetrahedral geometry and are often far less stable with 
lower formation constants (log b). Reduced Cu+ complexes are also kinetically labile and normally 
undergo rapid ligand exchange, leading to demetallation and potential loss of the copper ion in 
vivo to competing ligands such human serum albumin, ceruloplasmin and other copper-binding 
proteins. Single-crystal X-ray structures supported by Density Functional Theory (DFT) 
calculations have shown that tetra-coordinate Cu2+ complexes comprising asymmetric donor atom 
sets like N2S2 bis-thiosemicarbazonato ligands induce a twist distortion in the square planar 
geometry.23 While structural distortion induces a slight increase in thermodynamic stability of 
complexes like CuATSM/A, the twisted geometry lies intermediate between true square planar 
Cu2+ complexes and a tetrahedral geometry favoured for reduced Cu+ complexes. Hence, 
geometric distortion facilitates metal-centred reduction of Cu2+ complexes to give Cu+ species that 
rapidly demetallate in vivo due to their lower thermodynamic, kinetic and metabolic stability. For 
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this reason, N2S2 bis-thiosemicarbazonato ligands are typically not employed in the design of long-
circulating copper-radiolabelled mAbs. Instead, the majority of copper-radiolabelled mAbs 
concentrate on stabilising the Cu2+ ion, and have been developed around aza-macrocyclic-based 
chelates like NOTA, DOTA and TETA (Figure 3). Other Cu2+ chelates incorporate varying 
combinations of macrocyclic N-donors with other donor groups such as carboxylates, phosphates 
or heteroaromatic rings such as derivatised pyridines or imidazoles etc. 
  To best of our knowledge, only two different chelates, BAT and DOTA, have been used in 
the development of 64/67Cu-radiolabelled mAbs for imaging and RIT in human trials. In a 
pioneering Phase I/II clinical trial, Philpott et al. investigated the distribution and specificity of a 
64Cu-labelled murine mAb, [64Cu]-BAT-2IT-1A3, in 36 patients with suspected advanced primary 
or metastatic colorectal cancer.24 Imaging was compared with compared [18F]-FDG and the study 
found that [64Cu]-BAT-2IT-1A3 was more specific for detecting colorectal tumours than [18F]-
FDG which showed false positive indications in patients with inflammatory lesions. The sensitivity 
of [64Cu]-BAT-2IT-1A3 was found to be 71% per lesion and 86% per patient. The investigation 
also found that immuno-PET imaging with [64Cu]-BAT-2IT-1A3 offered diagnostic 
improvements over previously developed radioimmunoscintigraphy imaging using [111In]-HBED-
1A325  (63% per lesion and 76% per patient). Critically, follow-up studies found no adverse side-
effects from 64Cu-mAb administration. However, it was noted that in about 25% of patients, 
increased titres of human anti-mouse antibody (HAMA) were found. This immune response 
toward an administered mAb-based radiopharmaceutical can be minimised/avoided by the use of 
chimeric or fully humanised mAbs. Subsequent pre-clinical studies by Connett et al.26 showed the 
potential of both 64Cu and 67Cu-radiolabelled BAT-2IT-1A3 for RIT. Small GW39 tumours (~0.2 
g) showed 82% and 93% remission in tumour size when treating with 2.0 mCi of 64Cu- or 0.4 mCi 
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of 67Cu-BAT-2IT-1A3, respectively. Interestingly, larger tumours (~0.6 g) only showed growth 
inhibition but not regression, even when treating with higher doses of radioactivity. These data 
highlight an important limitation of using mAb-based drugs that often fail to penetrate fully into 
the core of larger solid tumours. 
 In the late 1990s, DeNardo and co-workers reported preclinical27 studies and clinical 
translation13,28,29 of the radiolabelled murine mAb, 67Cu-BAT-2IT-Lym-1, for RIT in patients with 
Non-Hodgkin’s lymphoma (NHL). In one study, O’Donnell et al.28 measured the dosimetry and 
pharmacokinetics of 67Cu-BAT-2IT-Lym-1 in 12 NHL patients with stage III or IV disease that 
had failed to respond to standard therapy. Patients received up to 4 separate doses of 67Cu-RIT at 
4 week intervals with administered activities between 0.93 – 2.22 GBq/m2/dose. The trial found 
that chemotherapy-resistant patients had a combined partial and complete response rate of 58% 
(7/12 patients). Radiation dosimetry measurements confirmed specificity of radiotracer uptake in 
tumours which led to disease lesions receiving the highest mean radiation dose (2.35±0.97 
Gy/GBq). Measurements also found favourable radiotracer distribution with tumour-to-
background organ ratios against marrow lung, kidney and liver of 28:1, 7.4:1, 5.3:1 and 2.6:1, 
respectively. In a follow-up study, Mirick et al.13 performed detailed analysis of the radiochemical 
stability of 67Cu-BAT-2IT-Lym-1. Transfer of 67Cu to ceruloplasmin was observed in all patients 
with an average of 2.8±1.5% of the initial dose being lost to ceruloplasmin in the liver. The release 
rate of 67Cu from 67Cu-ceruloplasmin in the liver to the blood was 0.9±0.4 %ID/day during the 
first 3 days post-radiotracer administration. The researchers noted that loss of 67Cu ions to 
endogenous proteins led to a biphasic clearance rate.  
 In efforts to increase the metabolic stability of 64/67Cu-radiolabelled mAbs, Lewis et al.30 
compared 64Cu-TETA-1A3 versus 64Cu-BAT-2IT-1A3 (Figure 4). Head-to-head experiments 
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showed that conjugation of the TETA chelate to the mAb via amide bond formation led to 
favourable serum stability, biodistribution, immunoreactivity and dosimetry properties. Alongside 
earlier work,31 these data demonstrate the importance of developing new chelating systems to 
increase the stability of Cu-based radiotracers in vivo. 
 Recent clinical studies using 64Cu-mAbs have tended to employ the DOTA chelate coupled 
to the mAb via amide bond formation. Clinical trials worldwide have reported the efficacy of using 
64Cu-DOTA-trastuzumab to measure expression of the human epidermal growth factor 2 
(HER2/neu) in breast cancer patients.32–34 In addition, 64Cu-labelled cetuximab for imaging 
epidermal growth factor receptor (EGFR) has been studied extensive in preclinical work with 
experiments comparing the performance of different chelates including DOTA,35,36 CB-TE1A1P, 
CB-TE1K1P in combination with either tradition amide bond coupling or ‘Copper-free Click’ 
methods for rapid bioconjugation.37 As efforts gather pace to improve access to 67Cu,18 
identification of new chelates, linkers and radiolabelling methods to produce 64/67Cu-mAbs is 
essential.  
 
3. Zirconium radiolabelled antibodies 
Over the last two decades, 89Zr (t1/2 = 78.41 h; b+ = 22.74%) has emerged as the most important 
radionuclide for immuno-PET.4 Elsewhere in this issue of Journal of Labelled Compounds and 
Radiopharmaceuticals, Viola-Villegas and co-workers present a detailed overview of progress 
made in the use of 89Zr-radiolabelled mAbs for clinical imaging. The follow section focuses on the 
radiochemistry and coordination chemistry of 89Zr4+ ions. The half-life of just over 3 days matches 
well with the extended circulation times of mAbs in the human body which facilitates accurate 
measurements of antibody pharmacokinetics at time points beyond 1 week after radiotracer 
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administration. The chemistry and radiochemistry of 89Zr offers a number of technological 
advantages over other radionuclides such as 64Cu. 89Zr is produced via low energy (ca. 13 – 15 
MeV) proton beam irradiation of commercially available 89Y solid metal foils.38 The 89Y target 
material has a natural isotopic abundance of 100%, which unlike 64Cu that requires recycling of 
isotopically enriched 64Ni electroplated targets, makes production of 89Zr comparatively cheap. 
Extraction methods are optimised and fully automatable yielding either 89Zr-tetraoxalate 
([89Zr(C2O4)4]4–) or 89Zr-chloride in high chemical and radiochemical purity, and high specific 
activity (470–1195 Ci/mmol).  
 The aqueous phase chemistry of zirconium is limited to the group oxidation state of 4+ 
with a d0 electronic configuration. The thermodynamic stability of Zr4+ complexes is dominated 
by electrostatic interactions with no contribution from crystal field stabilisation. The very high 
charge density of Zr4+(aq.) ions (ionic radius = 0.85 Å)21 induces significant bond polarisation in 
the first coordination sphere and the dative bonds have strong ‘covalent character’. The very low 
solubility product of Zr(OH)4 (log Ksp = 56.94±0.32)39 means that Zr4+ species have a strong 
tendency to hydrolyse and form colloidal species in aquo. Avoiding precipitation of Zr-oxo species 
requires the use of metal binding chelates that form exceptionally stable complexes with high-
valent metal ions. For this reason, most of the work using 89Zr-mAbs has employed the 
hexadentate, tris-hydroxamic acid chelate, desferrioxamine B (DFO). The formation constant of 
Zr-DFO has yet to be determined but experience has found that excess Fe3+ ions do not 
transmetallate with the preformed ZrDFO complex on a time scale appropriate for immuno-PET 
(Holland unpublished data). This observation suggests that either the ZrDFO complex is 
kinetically stable toward transmetallation with Fe3+ ions, and/or that the formation constant of 
ZrDFO is possibly higher than the reported thermodynamic stability of FeDFO (log b = 30.6).40 
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 It is notable that although DFO is an exceptionally powerful chelate for coordination of 
Zr4+ ions, zirconium has the ability to accommodate between 6 and 8 donor atoms in the first 
coordination. DFT calculations have indicated that DFO fails to fully saturate the first coordination 
sphere of Zr4+ ions and the ligand is quite strained.41,42 One or two vacant coordination sites are 
potentially occupied by labile water molecules or anions like chloride. Additional experiments 
using 89Zr-immuno-PET in rodent models have found elevated levels of activity accumulating in 
the bone over time. Interestingly, bone activity is typically higher when investigating tumour 
models that show positive expression of the target antigen than in models where tumour 
accumulation occurs via enhanced permeability and retention (EPR).41,43–45 These data point 
toward a specific intratumoural metabolism that leads to recirculation of unidentified Zr4+ species 
that sequester in the bone. Other studies have shown that [ZrDFO]+ is excreted rapidly via a renal 
clearance mechanism yet other species including a putative ‘89Zr-chloride’ in phosphate buffered 
saline, and [89Zr(C2O4)4]4– accumulate in liver and bone, respectively.38,46 Collectively, data 
suggest that 89Zr species with overall anionic charge have a higher propensity to sequester in bone. 
As previously mentioned for the 64Cu work, further studies are required to elucidate the nature of 
the radioactive metabolites that recirculate in vivo after release from tumours and potentially other 
background organs like the liver. We note that similar bone sequestration of 89Zr radioactivity has 
not been reported in human trials. Nevertheless, these preclinical data, combined with the fact that 
DFO does not fully satisfy the coordination requirements Zr4+ ions, have prompted recent efforts 
in the design and synthesis of alternative chelate systems for this radionuclide.47 A selection of 
recent bifunctional chelates that have been developed as potential alternatives to the ‘gold 
standard’ DFO chelates are presented in Figure 5.47–53 
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 Detailed DFT calculations explored the mechanism of ligand substitution between oxalate 
and hydroxamate ligands bound to Zr4+ ions.42 This computational study revealed a comprehensive 
set of ‘design criteria’ that can aid the synthesis of new chelates for selective, high affinity 
coordination of Zr4+ ions. New ligands should aim to incorporate hard, class A donor atoms in a 
ligand geometry that is pre-organised for coordination to Zr4+ ions. Since Zr4+ ions can 
accommodate between 6- to 8- donor atoms in the first coordination sphere, new chelates should 
aim to maximise thermodynamic and kinetic stability. Whilst increasing the denticity of a chelate 
has the general effect of increasing the thermodynamic and kinetic stability of a metal complex 
due to an increased chelate effect, there is no fixed rule that dictates 7- or 8-coordinate complexes 
are more stable that 6-coordinate complexes. Rather, the relative thermodynamic stability between 
6-, 7- and 8-coorindate complexes is a balance between the generally increased stabilisation 
acquired through coordination of an extra donor atom versus increased repulsive forces generated 
from increased steric crowding in the first coordination sphere and potentially increased strain 
induced in the ligand backbone. Furthermore, larger metal ion complexes with 8-coordinate 
geometries are likely to be more susceptible toward ligand exchange mediated by solvent (water) 
molecules. For maximum thermodynamic stabilisation of Zr4+ ions, ligand scaffolds should be 
carefully designed to increase the acidity of the donor atoms. This will potentially increase the 
degree of “covalent-character” bonding between the ligand and 89Zr4+ ions. To achieve this, donor 
atoms should be part of strongly acidic groups. Suitable functional groups that have been used in 
the design of successful Zr4+ chelates include carboxylic acids, phosphates, hydroxamic acids, 
phenols, catechols, and hydroxypyridinonates (Figure 5).  
 Desferrioxamine B is a natural product produced by bacteria and acts as a siderophore, 
extracting Fen+ ions from highly insoluble iron oxides (the log Ksp (Fe(OH)3 lies between 10-37 and 
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10-44 depending on the conditions).54 Extracting iron from soil requires very powerful chelates 
which can pose a potential problem for radiochemistry with 89Zr4+ ions. While [Zr(DFO)]+ is stable 
with respect to transmetallation by Fe3+ ions, care must be taken to ensure that no iron 
contaminants are present in any of the solutions used for 89Zr4+ extraction or radiolabelling. 
Experience has found that trace amounts of Fe3+ ions act as efficient ‘poisons’ toward 89Zr 
radiochemistry. Since the majority of new chelates designed for coordination of 89Zr4+ ions are 
based on, or inspired by, the structures of siderophores, working with high-purity metal ion free 
solutions is essential to ensure that radiolabelling proceeds efficiently, and generates products with 
high radiochemical purity and effective specific activity. In spite of these challenges, efficient 
protocols have been reported for producing many 89Zr-DFO-mAbs.43,55 We note that although 
several bifunctional chelates have been produced and claimed to be superior in terms of 
radiochemical stability toward transchelation of Zr4+ ions, it is yet to be seen if any of these new 
ligands will emerge as a genuine competitor to DFO. In the clinical setting, DFO has a number of 
strong advantages that present a very high barrier for any alternative chelate to cross. For instance, 
DFO is a US-FDA approved drug, it is readily available and cheap, has good solubility properties 
(unlike many new chelates), and chemical methods for attaching DFO to mAbs are highly 
reproducibly, efficient and now practiced as routine in many radiochemistry facilities. As clinical 
trials using 89Zr-DFO-mAbs accelerate, and generally image quality from reported clinical trials 
is considered excellent with no loss of radiometal to the bone, these positive experiences will make 
many physicians reluctant to venture into uncharted waters without obvious need or benefit. In 
addition, the costs of generating essential toxicological studies of a new chelate prior to clinical 
translation may prove prohibitive for most second-generation chelates. The question that must be 
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addressed by any new radiotracer (or here chelate) is, how much better must a new tool be to cause 
the Nuclear Medicine community to shift from a well-established, reliable and trusted technology? 
 While the ability to image mAb distribution over the course of several weeks can be 
considered an advantage, the major limitations of 89Zr-mAbs are the comparatively poor dosimetry 
profile and the practical challenges of managing patients who receive a 89Zr radiotracer injection 
and remain radioactive for extended periods of time. Long circulation times with limited excretion 
mean that 89Zr-mAb radiotracer doses are limited to ~185 MBq56–58 with typical doses of, for 
example, 89Zr-DFO-trastuzumab for imaging HER2/neu expression in breast cancer patients 
around 37 MBq/patient. As an initial tool to validate the usefulness of a new biomarker, 89Zr-mAbs 
remain an excellent choice. However, as alternative radiotracers based on small-molecules are 
developed to image the same targets, for example 68Ga-urea-based Glu-NH-C(O)-NH-Lys 
compounds for PET imaging of prostate-specific membrane antigen (PSMA) agents, practical 
considerations are likely to dictate the long-term future of 89Zr-mAbs.  
 
4. Gallium-67 radiolabelled antibodies 
Gallium-67 radiolabelled mAbs were amongst some of the first antibody-based radiotracer tools 
developed for radioimmunoscintigraphy and immuno-SPECT.59 The radiochemical properties of 
67Ga (t1/2 = 3.26 d; ε = 100%), with intense Auger electron emissions and various g-rays emitted 
in the range 8 – 887 keV make this radionuclide suitable for both imaging and RIT with mAbs. 
Similar to 89Zr, 67Ga3+ exist in the group oxidation state with no redox chemistry. The 
thermodynamic stability of Ga3+ complexes is dominated by electrostatic interactions with a strong 
preference for hexadentate chelates proffering hard, class A donor atoms. In addition, the high 
charge density of Ga3+ ions (ionic radius = 0.62 Å)21 leads to a high propensity of Ga complexes 
 Page 16 
 
to hydrolyse in aqueous solution, potentially forming Ga-colloidal species of uncertain chemical 
composition. Stabilising Ga3+ ions against rapid hydrolysis and formation of either gallium 
tetrahydroxide anions (Ga(OH)4–) or Ga-colloids requires careful control of the reaction buffer 
composition, ionic strength and pH, and the use of chelates that form Ga complexes with very high 
formation constants. Chelates of choice for Ga3+ radionuclides include bifunctional derivatives of 
DFO, EDTA and various aza-macrocycles primarily based on the structures of NOTA and DOTA 
(Figures 3 and 5). Indeed, Koizuma et al. reported efficient radiolabelling of 67Ga-DFO-mAbs in 
1988. Interestingly, they also tested the stability of different coupling strategies and found that the 
use of glutaraldehyde coupling led to high non-specific uptake in liver and spleen. In contrast, 
67Ga-DFO-mAbs linked via thioether bonds (maleimido chemistry) displayed the highest tumour-
to-liver ratios, and radiotracers produced using disulphide bridges were unstable, with activity 
cleared rapidly from circulation. Nowadays, alternative methods for mAb coupling and different 
chelates for Ga3+ ion coordination are available but DFO remains a competitive choice.60 With a 
prevailing shift toward immuno-PET, development of 67Ga-mAbs has stagnated in recent years. 
Nevertheless, as research efforts aimed at delivering an Auger-emitting radionuclide to the cell 
nucleus intensify, 67Ga has potential to see a resurgence in interest. A recent article by Othman et 
al. reassessed the therapeutic potential of 67Ga and concluded that on a per cell basis, 67Ga causes 
as much damage as 111In to plasmid DNA.61  
 
5. Indium-111 radiolabelled antibodies 
Since the 1980s, 111In-radiolabelled mAbs have been developed as tools for 
radioimmunoscintigraphy, immuno-SPECT and for RIT. The radionuclide 111In (t1/2 = 2.80 d; ε = 
100%) decays with intense low energy Auger electron emission (2.72 keV, 100%) and also emits 
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a number of g-rays whose energy and intensity (171 keV [90.7%]; 245 keV [94.1%]) are ideally 
suited for high resolution SPECT imaging and targeted RIT.  
In the following examples of 111In-mAbs, DTPA was used as the chelate for coordination 
of the 111In3+ ion. Indium lies underneath gallium in group 13 (group 3A) of the Periodic Table. 
As such, the chemistry of In3+ and Ga3+ ions are quite similar. One notable difference is that In3+ 
ions have a larger ionic radius (0.80 Å)21 and can accommodate additional donor atoms in the first 
coordination sphere. In this regard, the coordination requirements of 111In3+ lie between Ga3+ and 
Zr4+ ions, and for this reason, DTPA (which offers up to nine, class A, hard donor atoms) remains 
the primary chelate used for 111In3+ coordination. To the best of our knowledge, little work has 
been reported on the development of alternative chelates for specific coordination of 111In3+ ions. 
However, as discussed for 67Ga, the resurgence of interest in targeted RIT using Auger emitters is 
likely to stimulate radiochemists to revisit the coordination chemistry and radiochemistry of 111In.  
 Indeed, early clinical studies reported by Ryan et al.62 found that imaging was able to detect 
breast lesions in breast cancer patients infused with varying doses of different human IgM 
monoclonal antibodies 111In-YBB-190, 111In-YBB-209 or 111In-YBB-088. However, antigen 
expression levels and mAb dose were critical factors in determining the success of diagnostic 
imaging with 111In-mAbs. 
 One of the earliest radiolabelled mAbs to receive US-FDA approval (in 1996) for imaging 
was 111In-capromab pendetide (111In-7E11; ProstaScint®). 111In-capromab pendetide is a mouse 
mAb that recognizes a specific intracellular epitope of prostate specific membrane antigen 
(PSMA) and can be used for immuno-SPECT imaging of prostate cancer soft tissue metastases. 
Unfortunately, targeting an intracellular epitope led to sub-optimal performance of this radiotracer 
in clinical diagnosis of prostate cancer with fairly low sensitivity for viable tumour lesions (62% 
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for lymph node metastases; 50% for prostate bed recurrence). Furthermore, 111In-capromab 
pendetide was not able to identify prostate cancer lesions in bone which is the most common site 
of metastatic disease in this patient population. Subsequent preclinical and clinical studies using 
89Zr-DFO-J591 to image an extracellular epitope of PSMA mean that 89Zr-immuno-PET has 
largely superseded the need for 111In-ProstScint scans. Despite limitations, 111In-capromab 
pendetide remains available on the market.  
 Several other 111In-mAbs have previously received US-FDA approval include 111In-
satumomab pendetide (OncoScint®) for imaging TAG-72, a tumour-associated antigen found on 
~95% of colorectal carcinomas and 100% of ovarian carcinomas; 111In-imiciromab-pentetate 
(MyoScint®), a murine mAb Fab-fragment directed against human cardiac myosin and formerly 
used for cardiac imaging; 111In-igovomab (Indimacis-125®), a mouse F(ab’)2 fragment for 
imaging carcinoma antigen 125 (CA-125) in the diagnosis of ovarian cancer. However, each of 
these 111In-radiotracers has subsequently been withdrawn.2  
   
 
6. Technetium-99m radiolabelled antibodies 
Technetium-99m (t1/2 = 6.01 h; IT = 100%) is the most common radionuclide used to develop 
SPECT radiotracers.63 In contrast to many other radionuclides described here, the chemistry of 
99mTc is highly diverse. Technetium lies in group 7B of the Periodic Table, underneath manganese, 
and as such, exhibits a rich redox chemistry. 99mTc species in a wide range of oxidation states from 
–1 to +7 have been reported. Variable oxidation states mean that Tc complexes are potentially 
redox active, implying that 99mTc-complexes must be designed to be thermodynamically and/or 
kinetically stabile toward redox reactions in vivo. The majority of radiotracers have been 
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developed around 99mTc5+ and 99mTc+ ions. A unique feature of 99mTc radiochemistry is the concept 
of utilising different ‘99mTc-cores’ with the three most common being {99mTc=O}, {99mTcO3} and 
{99mTc(CO)3} (Figure 6).63 
 During the mid-1990s to mid-2000s, a number of 99mTc-mAbs received market approval.2 
For example, 99mTc-nofetumomab merpentan (Verluma®) is a mouse mAb Fab-fragment attached 
to a merpentan chelate and used for imaging the pan-carcinoma glycoprotein antigen EpCAM 
and/or CD20/MS4A1 in cancers of the lung, gastrointestinal tract, breast, ovary, pancreas, cervix, 
kidney and bladder. Verluma® was approved in 1996 but withdrawn in 1999. 99mTc-
arcitumomab (CEA-Scan®) is a mouse Fab’ fragment developed by Immunomedics to target the 
Carcinoembryonic antigen (CEA) cell-adhesion proteins which are biomarkers on various cancers 
including colorectal tumours. CEA-Scan® was approved in 1996 but withdrawn in 2005. 99mTc-
sulesomab (LeukoScan®) received approval in 1997 and is a mouse Fab’ fragment that targets 
granulocyte cell antigen NCA-90 and is used for imaging infections and inflammations in patients 
with suspected osteomyelitis. LeukoScan® is also being investigated in the evaluation of soft 
tissue infections.64 99mTc-votumumab (HumaSPECT®) is a human monoclonal antibody for 
detection of 3-fucosyl-N-acetyl-lactosamine (CD15) expression in colorectal tumours. Although 
HumaSPECT® received approval in 1998, it was withdrawn in 2004 without being made available 
on the market. Finally, 99mTc-fanolesomab (NeutroSpec®) is a mouse mAb developed to target 
CD15 and received approval in 2004 for diagnosis of appendicitis. However, in December 2005 
the US-FDA issued an alert and NeutroSpec® marketing was voluntarily suspended due to reports 
of serious and life-threatening cardiopulmonary events that followed immediately after 
NeutroSpec® administration. Two deaths were reported and further patients experiences serious 
complications including cardiac arrest, hypoxia, dyspnea and hypertension. While these adverse 
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reactions were most likely due to a reaction to the antibody-component and not the radionuclide, 
it offers a lesson that, as with chemotherapeutic drugs, full preclinical characterisation of 
radiotracers is crucial before translation to the clinic.  
 
7. Iodine radiolabelled antibodies 
Although not radiometals, iodine radionuclides remain among the most frequently utilised 
therapeutic isotopes in the clinic. The radionuclide of primary interest is 131I due to its dual 
emission capabilities. 131I (t1/2 = 8.1 d) emits β– particles (average energy of 192 keV with a range 
of 0.8 mm in tissue) as well as a concomitant γ-emission (364 keV) suitable for SPECT imaging.65 
131I is a reactor-produced isotope, conveniently accessible from 235U fission products.66 However, 
123I and 125I have also become of interest due to their potential for either imaging or Auger therapy 
applications, respectively. The photon energy of 125I is considered too low for optimal imaging, 
especially for quantitative imaging, and its half-life is undesirably long. Thus, 125I is typically used 
for in vitro applications and radioactive binding assays.67 124I (t1/2 = 4.2 days) has a relatively low 
ratio of disintegration resulting in positrons (about 23%), and a complex decay scheme which 
includes high-energy gamma emissions (highest about 1.7 MeV). It is typically produced by using 
enriched 124Te via the 124Te(d,2n)124I reaction or in recent years, the 124Te(p,n)124I reaction.68 
 In contrast to radiolabelling with metal ions, incorporation of iodine radionuclides requires 
formation of covalent bonds. Typically, radioiodine is introduced using mild oxidative reagents 
that minimise potential chemical degradation of mAbs. Chloramine-T (N-chloro-p-toluene 
sulfonamide) is an aromatic oxidising agent commonly used for this purpose, but requires close 
monitoring and quenching of the reaction before excessive mAb oxidation occurs (Figure 7).69 The 
use of solid-support chloramine-T provides a milder radiolabelling alternative, allowing for 
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filtration workups as a way to rapidly remove the oxidant.70 Another commonly used oxidizing 
agent employed is iodogen (1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril).71 Other methods 
involve radioiodination of an activated-ester small molecule (N-succinimidyl 3-(4-hydroxyphenyl) 
propionate; Bolton-Hunter reagent) with chloramine-T, followed by mAb conjugation in a 
secondary step.72 
 [131I]NaI-mediated treatment of malignant thyroid disorders has represented a mainstay of 
RIT in the clinic. Recently, 131I-mAbs are becoming of greater interest for targeted cancer therapy. 
131I-tositumomab (Bexxar®) is the earliest representative of this compound class. 131I-
tositumomab is used to treat certain types of NHL.73 Investigations have also sought define the 
role of 131I-tositumomab RIT in treating Hodgkin’s lymphoma, diffuse large B-cell lymphoma,74 
and multiple myeloma.75 Based on the promising outcomes in clinical studies, 131I-tositumomab 
was approved by the FDA for clinical practice in patients with lymphoma. 131I-Lym-1 (Oncolym®) 
is an 131I-radiolabelled mAb in Phase III clinical trials for non-Hodgkin’s lymphoma.76 Cotara® is 
a genetically engineered chimeric human/mouse mAb that binds to the DNA-histone H1 complex, 
targeting the necrotic core of solid tumours.77 Phase II clinical trials on patients with astrocytoma, 
brain gliobastoma, hepatocellular carcinoma (HCC) have shown promising results.78 Similarly, the 
treatment was also found to be successful in lung cancer patients via intratumoral injections.79 
 Until recently, iodine-124 was not considered to be an attractive isotope for medical 
applications owing to its complex radioactive decay scheme, which includes several high-energy 
g-rays. Limited availability of this radionuclide has also impeded its clinical application. Among 
clinically assessed 124I-radiotracers, sodium [124I]-iodide is potentially useful for diagnosis and 
dosimetry in thyroid disease and [124I]-M-iodobenzylguanidine ([124I]-MIBG) has shown promise 
for cardiovascular imaging as well as dosimetry of malignant diseases such as neuroblastoma, 
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paraganglioma, pheochromocytoma, and carcinoids.80 A number of monoclonal antibodies have 
been labelled with 124I and imaged successfully in mouse models.81,82 As with several other 
radionuclides, interest in 124I-mAbs has waned in light of the success of 89Zr-mAbs in preclinical 
and clinical settings.  
 
8. Yttrium radiolabelled antibodies 
90Y is a widely used radiometal for β− therapy. With a half-life of 2.67 days, it decays via β− 
emission (100%) with a maximum β-particle energy of 2.288 MeV, providing a greater penetration 
range in vivo than many other β− emitting nuclides.12,83 90Y may be produced using various nuclear 
reactions. Irradiation of 89Y in a nuclear reactor produces 90Y, however, this route generates an 90Y 
product with low specific activity that is inseparable from the target material. No-carrier added 90Y 
can be obtained by separation of 90Y from 90Sr (t1/2 = 28.5 y). Currently, the separation of 90Y is 
carried out at production sites, and the long half-life of 90Sr could enables manufacture of a 
generator system comparable to the 99Mo generator for 99mTc. 90Sr is one of the most abundant 
fission product radionuclides in spent nuclear fuel as it is generated in high yield.84 The high β− 
energy renders 90Y suitable for treatment of larger, poorly vascularized tumours (approximate β− 
range of ∼12 mm in addition to extended therapeutic range through the “crossfire effect”). More 
recently, in addition to accessibility of 90Y as a therapeutic isotope, the PET isotope 86Y has 
emerged as the imaging congener. Currently, primary limitations of use of 86Y clinically are its 
non-ideal emission characteristics: β+ emissions (2.019, 2.335 MeV) are sub-optimal for imaging 
due to their high energy leading to decreased image resolution, and poor radiation dosimetry 
profile arising from high-energy γ–ray emissions (1.077, 1.153, 1.854, 1.921 MeV).85 
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 Y3+ has an ionic radius of 1.02 Å, an absolute electronegativity of 41.2 eV and a hardness 
of 20.6 eV.86 It ranks among the hardest trivalent ions, exhibiting a strong preference for oxygen 
and nitrogen donors. Most frequently used chelates for coordination of 86Y/90Y are DOTA87 and 
CHX-A′′-DTPA88 (Figure 3). Main issues identified with these established ligand systems include 
slow complexation kinetics at room temperature (DOTA), and/or decreased stability in vivo 
(DTPA-derivatives).89 To leverage the enhanced kinetic stability of macrocycles and rapid 
chelation of acyclic systems, Kang et al. have synthesised the bimodal ligands 3p-C-NETA and 
3p-C-DEPA (Figure 8) that possess both macrocyclic and acyclic moieties for cooperative metal 
ion binding. Radiolabelling of these chelates also shows favourable radiochemical yields under 
mild conditions (room temperature, pH 5.5, 60 min).90 However, only 3p-C-NETA exhibited 
sufficiently high kinetic stability in plasma challenge experiments. Price et al. evaluated the acyclic 
bifunctional chelator p-NCS-Bn-octapa-NCS (Figure 8) in comparison with CHX-A′′-DTPA and 
found that the 90Y-octapa complex exhibited increased plasma stability while maintaining 
equivalent in vivo performance when conjugated to trastuzumab.91 
 The 64-hour half-life and therapy-avid, γ-emission-free nuclear properties have contributed 
to the clinical success of 90Y in recent years. Ibritumomab tiuxetan (Zevalin®) is an FDA-approved 
90Y-radiolabelled mAb that combines DTPA linked to ibritumomab, allowing for the targeted 
irradiation with β-particles in B cell non-Hodgkin’s lymphoma.92 A number of new 90Y-labelled 
mAbs and antibody fragments are currently being assessed for efficacy in clinical trials. 90Y-
labelled basiliximab and daclizumab93 for Non-Hodgkin lymphoma, as well as 90Y-labelled 
microbeads (under the trade names TheraSphere and SIR-Spheres) have obtained FDA approval 
in 1999 and 2002 for the treatment of non-resectable liver cancer and other applications of 
radioembolization.94 CD22-targeting 90Y-labelled epratuzumab is currently evaluated in a Phase 
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III trial for the treatment of lymphoma, leukaemia and some immune diseases.95 Work by Salako 
and co-workers investigating 90Y-BAT-Lym1 in comparison with the 131I and 67Cu-labeled 
analogue showed decreased efficacy when compared with Lym1 labelled with other therapeutic 
isotopes.96 Beyond mAb-based agents, 90Y-labelled DOTATOC (somatostatin-conjugate) is also 
under clinical investigation for the treatment of larger neuroendocrine tumours.97 
 
9. Lutetium-177 radiolabelled antibodies 
177Lu (t1/2 = 6.6 days) is a mixed mode β− and γ–ray emitting radionuclide. It decays with emission 
of β− particles of 176 (12%), 384 (9%), and 497 keV (79%) as well as γ–rays with energies of 208 
(11%) and 113 (6.6%) keV rendering this isotope suitable for SPECT imaging and RIT.83 177Lu is 
typically obtained using reactors by neutron irradiation of 176Lu to afford 177Lu in high yields,98 
satisfactory specific activities. However, reactor production yields both the desired 177gLu and the 
excited state 177mLu as a radionuclidic impurity. 177Lu can also be produced by neutron activation 
of enriched 176Yb to afford 177Yb (1.9 h half-life), which then decays to 177Lu.99 This synthesis 
produces higher specific activities and a no-carrier added product, which more desirable for the 
labelling and in vivo imaging of low-abundance biological targets. The β− emission of 177Lu has 
an approximate range of 2 mm in vivo, ideal for irradiation of smaller tumours and metastases. 
 As the element with the greatest number of protons of the lanthanide series, Lu3+ 
experiences the strongest Lanthanide contraction of ionic radius, ranging from 0.98 Å 
(coordination number 8) or 1.03 Å (coordination number 9). Lu3+ can be considered a hard Lewis 
acid with an absolute electronegativity of 33.1 eV and a hardness of 12 eV.86 Depending on the 
steric crowding of the coordinating chelate, Lu3+ ions commonly form complexes of coordination 
number 8 or 9. Both cyclic and acyclic chelators have been utilised for this metal ion, specifically 
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DTPA, CHX-DTPA and DOTA.100,101 The slow rate of complexation of DOTA-based ligands with 
177Lu becomes a significant disadvantage for preparation of DOTA-based radiopharmaceuticals. 
For this reason, heating becomes essential in most cases in order to increase the complexation rate 
Generally, heating at 95 °C for 25–30 min is performed in order to achieve near quantitative 
radiolabelling yields for the preparation of 177Lu–DOTA-conjugated somatostatin analogues. 
DOTA–affibodies have been radiolabelled with 177Lu under heating at lower temperature (60 °C) 
to obtain high-efficiency labelling. Whole antibodies are typically labelled either at room 
temperature or 37 °C, in order to not jeopardise the integrity of the protein. Typically, this results 
in less than quantitative radiochemical labelling yields for 177Lu-mAbs or the need to employ 
reaction times of 1 hour or longer to achieve quantitative complexation of the radionuclide. Once 
DOTA-type complexes are formed, they exhibit high kinetic and thermodynamic stability, with no 
significant dechelation reported in vivo, even after long circulation times typical for mAbs. The 
chelates 3p-C-NETA and 3p-C-DEPA (Figure 8) as synthesized by Kang et al.90 and evaluated 
with 90Y (vide supra) have also shown promise, with near-quantitative 177Lu labelling yields under 
mild conditions (room temperature, pH5.5, 60 min). The trastuzumab conjugate of 3p-C-NETA 
showed high in vivo stability, high tumour uptake and low accumulation in off-target organs. 
Similarly, trastuzumab conjugates with the acyclic octadentate chelator p-SCN-Bn-octapa (Figure 
8) can be labelled with 177Lu at room temperature within 15 minutes.102 This is in contrast with the 
corresponding DOTA conjugate, which requires 37 °C and extended reaction times (60 min.) to 
achieve 85% radiochemical yield. Both of these trastuzumab conjugates exhibited identical 
behaviour in vivo. Octapa-derivatives represent a ligand class that provides an attractive alternative 
to ‘gold standard’ DOTA derivatives due to their improved radiolabelling characteristics. 
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 The extent of preclinical studies has been reviewed by Banerjee et al.103 In terms of clinical 
studies, 177Lu has witnessed increasing use. The 6.6 day half-life is suitable for use with both 
peptides and mAbs as targeting vectors. The long half-life is also suitable for access to 177Lu-
therapy in hospitals that do not have access to reactor or cyclotron facilities. The non-quantitative 
radiolabelling yields of 177Lu with mAb conjugates due to sub-optimal radiolabelling protocols to 
is one potential reason that has limited a more wide-spread adoption of 177Lu-mAbs in the clinic. 
Beyond mAb-based agents, 177Lu-DOTATOC/DOTATE has been found to be highly effective for 
the treatment of neuroendocrine tumours and is currently under regulatory review,104,105 while the 
imaging-only analogue 68Ga-DOTATE (NETSPOT®) obtained FDA approval in 2016. 
 
10. Lead-212 radiolabelled antibodies 
212Pb is produced by the decay chain originating from 232U (228Th decay chain) and can be obtained 
from a generator made from 224Ac or 224Ra. 212Pb (t1/2 = 10.6 h) is a b-emitter (100%, 570 keV), 
but is primarily of interest as the parent nuclide of the a-emitting short-lived 212Bi (t1/2 = 60.6 min) 
and 212Po (t1/2 = 0.3 µs) with deposited energies of 21.1% from the 6.2 MeV 212Bi α-particle 
emission and 67.3% from the 8.9 MeV 212Po α-particle emission.106 212Pb/212Bi is considered an in 
vivo generator system.107 212Pb itself can be obtained by way of the 224Ra/212Pb generator. 
However, the short half-life of 224Ra (t1/2 = 3.7 d) requires frequent replacement in a clinical setting, 
similar to the 99Mo/99mTc generator system.108 The original generator system was developed in 
1989, but in recent years, rekindled interest in a-therapy has resulted in commercial availability. 
 Pb2+ is a post-transition group 14 metal with ionic radius of 1.29 Å, an electronegativity of 
23.5 eV and an absolute hardness of 8.5 eV while Bi3+ is a group 15 metal with an ionic radius of 
117 ppm and an absolute hardness of 10.0 eV.86 The chelation chemistry of 212Pb faces the 
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challenge of having to conform to the coordinative preferences of not just Pb2+ but also Bi3+. An 
additional challenge is posed by the emission of Auger electrons and high recoil energy upon decay 
to 213Bi which can result in significant radiochemical degradation to the conjugated biomolecule. 
Initial studies using DOTA conjugates indicated loss of 212Pb from the bioconjugate and thus 
enhanced radiotoxicity.109 TCMC (Figure 8), a tetramide analogue of DOTA was developed and 
found to exhibit enhanced kinetic stability with both Pb2+ and Bi3+. The bifunctional, backbone-
functionalised version of TCMC has been successfully utilised for conjugation to mAbs and 
subsequent preclinical and clinical application.110 
 Prominent early preclinical studies with 212Pb/212Bi include treatment of EL-4 ascites and 
more contemporarily successful peptide-based metastatic melanoma treatment.111 A study on 
treatment of breast cancer xenografts with trastuzumab-linked 212Pb-TCMC showed highly 
promising outcome, providing the basis for human trials.112 A Phase I trial of 212Pb-TCMC-
trastuzumab for treatment of HER2-overexpressing cancers has recently been completed. 
 
11. Bismuth-213 radiolabelled antibodies 
213Bi is a short-lived isotope (t1/2 = 45.6 min) and decays by a emission (2%, 5.8 MeV) followed 
by two b emissions, or b emission (98%) followed by an a emission (8.4 MeV) and subsequent b 
emission to stable 209Bi. In addition, a 440 keV (26%) photon can be utilised for dosimetry via 
imaging. 213Bi can be obtained from 225Ac as part of the 225Ac/213Bi generator.113 A clinically-used 
generator has been developed and is commercially available for the supply of 213Bi. 
 The properties of the Bi3+ ion have been described in the 212Pb section (vide supra). In the 
case of 213Bi, no prior coordination of a softer metal ion is required as 213Bi is directly eluted from 
the 225Ac/213Bi generator. Thus, bifunctional versions of DOTA are suitable for the incorporation 
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of 213Bi into targeting vectors, but are often found to exhibit slow chelation kinetics at room 
temperature, and therefore, are not compatible with mAbs.114 DTPA chelates 213Bi more rapidly 
but the resultant 213Bi-DTPA complex exhibits low kinetic stability.115 Recent efforts have 
produced mixed macrocyclic systems with acyclic donor components (3p-C-NETA, 3p-C-DEPA, 
Figure 8) that provide more rapid chelation and enhanced kinetic stability of the resulting 
radiochemical complex.90,114 Ideal radiolabelling conditions encompass pH5.5 at room 
temperature. Another chelating system developed specifically for the Pb2+/Bi3+ pair is Me-do2pa 
by Lima et al. which displays favourable complexation kinetics and high thermodynamic stability. 
Additional radiochemical studies are underway.116,117  
The short half-life of 213Bi is not ideally matched with the typical pharmacokinetics of 
mAbs. However, a preclinical study with 213Bi-labelled J591 (antibody against PSMA) found 
complete inhibition of tumour growth, outlining the potential of this conjugate for application in 
humans.118 213Bi-lintuzumab (213Bi-HuM195 for acute myeloid leukaemia) was part of a clinical 
trial, and used in combination therapy with chemotherapy.119 Recent applications of 213Bi are 
centred on more rapidly targeting vectors such as DOTATOC/DOTATE and PSMA-617.120,121 
 
12. Actinium-225 radiolabelled antibodies 
225Ac has a 10-day half-life and decays to its short-lived daughter isotope 213Bi, also an a-emitter. 
225Ac is provided by three main suppliers: the Institute for Transuranium Elements in Germany, 
Oak Ridge National Laboratory in USA and the Institute of Physics and Power Engineering in 
Obninsk, Russia. The current worldwide production of 225Ac is approximately 1.7 Ci per year, 
which would only provide treatment for a small 100-200 patient cohort. Thus, new or more 
efficient methods of 225Ac production and isolation are needed. The common approach for 225Ac 
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production is separation from its mother nuclide 229Th (a daughter of 233U) or irradiation of 226Ra 
or a thorium target with protons in a cyclotron.122 225Ac decays123 to a cascade of 6 daughters until 
stable 209Bi is obtained, producing in total 4 a- and 3 b- emissions. Some of the intermediate 
daughters in the decay include 221Fr (t1/2 =4.8 min), 217At (t1/2 = 32.3 ms), and 213Bi (t1/2 = 45.6 
min), each of which emits an a-particle. 213Bi also emits a 440 keV γ-ray suitable for imaging. 
 The lack of stable isotopes of actinium has provided few opportunities to study its 
coordinative properties. However, recent EXAFS studies have shed light on some characteristics 
of Ac3+ as well as coordinative preference. Ac3+ has an ionic radius of 1.12 Å, and absolute 
hardness of 14.5 eV.86 XAFS studies on the Ac3+ (aq.) complex revealed a coordination number 
of 10-11, predicting a need for polydentate chelators beyond the usual octadentate DTPA and 
DOTA-type chelators.124,125 Limited studies have been carried out on the development of novel 
chelators for this radionuclide, but reported work includes extended polyaza-macrocycle systems 
HEHA and PEPA.126 However, radiolabelling properties and in vivo stability did not significantly 
improve when compared with DOTA, underscoring the need for novel, custom bifunctional 
chelators for Ac3+. This need has been addressed by recent work from Wilson and co-workers by 
development of the extended macrocyclic chelator macropa (Figure 8) and its bifunctional 
analogue. Macropa incorporates ether and amino donors within the macrocycle as well as bidentate 
picolinate donor arms to match the size and hardness of Ac3+, showing promise for targeted 
applications.127 
 Due to the limited access to 225Ac, only a handful of human studies have been carried out, 
but both preclinical and clinical work on therapeutic applications of this isotope has provided 
promising treatment outcomes. Multiple clinical trials involving 225Ac lintuzumab, an anti-CD33 
mAb (HuM195) for the treatment of acute myeloid leukemia are on-going, taking advantage of the 
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multi-daughter decay scheme of 225Ac as an advantage over the 213Bi-analogue; Preliminary data 
shows a three orders of magnitude greater potency of 225Ac-HuM195 when compared with 213Bi-
HuM195 (www.clinicaltrials.gov).128 
 
13. Conclusion 
The wide range of nuclear properties and half-lives of radiometals represent a tremendous 
opportunity to develop the next generation of imaging agents and therapeutics for personalised 
medicine. As the number of radiopharmaceuticals for imaging in the clinic increases, the 
switch in focus from diagnostic imaging to targeted radiotherapy is likely to continue in the 
near future. Given the importance of mAbs as biologics, radiotracers for RIT are set to become 
more prominent players in the nuclear medicine arsenal. In this context, as the personalised 
medicine gains traction, the need for radiometals will grow. The combination of imaging 
(pharmacokinetics, clearance, dosimetry) to optimize subsequent therapy provides a unique 
approach to treatment planning and will lead to an increased number of favourable clinical 
outcomes. Currently, there is need for new bifunctional chelates that offer improved 
radiolabelling characteristics for many radiometal systems including established radionuclides 
like 64Cu, 67Ga, 89Zr, 111In and 177Lu, as well as emerging radionuclides like 212Pb and 225Ac. Progress 
in this arena is key to propel non-standard radionuclides into the mainstay of nuclear medicine, 
radiology and oncology. 
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Figure 1. Stacked bar chart showing the total number of US-FDA approved New Molecular 
Entities from 2011 until August 2017 with a breakdown showing the contribution from mAb-based 
agents and other drugs. * Data available until 08/2017. 
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Figure 2. Schematic representation of a radiolabelled mAb involving chemical modification of 
the protein using covalent bond formation to a radiometal binding chelate via a linker group.  
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Figure 3. Chemical structures of selected chelates that have been employed for complexation of 
various radiometal ions including those of copper, gallium, indium, yttrium, lutetium, actinium 
and beyond.  
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Figure 4. Chemical conjugation of TETA and BAT-2IT to antibodies coupling to the e-NH2 group 
of lysine residues.  
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Figure 5. Chemical structures of selected bifunctional chelates that have been developed for 
derivatisation of proteins and complexation of 89Zr4+ ions.  
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Figure 6. Chemical structures of 99mTc chelates that incorporate different ‘99mTc-cores’. 
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Figure 7. Chemical structures of various reagents used for oxidative radiolabelling of proteins 
with iodine radionuclides.  
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Figure 8. Chemical structures of selected chelates that have been employed for complexation of 
yttrium, lutetium, bismuth, lead and actinium.  
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Table 1. Physical decay characteristics of various radionuclides that have potential applications in 
diagnostic imaging and radioimmunotherapy with antibody-based radiopharmaceuticals. 
Radionuclide Half-life, t1/2 Decay mode  
(% branching ratio) 
Production route(s) GS-GS Q-value 
(keV) 
Particle end-point 
energy / keV  
Application 
64Cu 12.701 h ε+β+ (61.5%) 
β+ (17.60%) 
β- (38.5%) 
64Ni(p,n)64Cu 1675.03 (64Ni) 
579.4 (64Zn) 
β+ 653.03 
β- 579.4 
Immuno-PET and 
RIT 
67Cu 61.83 h β- (100%) 68Zn(p,2p)67Cu 
70Zn(p,a)67Cu 
67Zn(n,p)67Cu 
68Zn(g,p)67Cu 
561.7 β- 561.7 RIT (Immuno-
SPECT) 
67Ga 3.2617 d ε (100%) natZn(p,x)67Ga 
68Zn(p,2n)67Ga 
1000.8 Auger and CE Immuno-SPECT 
and RIT 
86Y 14.74 h ε+β+ (100%) 
β+ (31.9%) 
86Sr(p,n)86Y 5240 β+ 3141 Immuno-PET 
89Zr 78.41 h ε+β+ (100%) 
β+ (22.74%) 
89Y(p,n)89Zr 2833 β+ 902 Immuno-PET 
90Y 64.00 h β- (100%) 90Sr/90Y 2280.1 β- 2280.1 RIT 
99mTc 6.01 h β- (0.0037%) 
IT (99.9963%) 
99Mo/99mTc Excited state 
(parent) level: 
142.68 
β- 435.9 Immuno-SPECT 
111In 2.8047 d ε (100%) 111Cd(p,n)111m,gIn 
112Cd(p,2n)111m,gIn 
862 Auger and CE Immuno-SPECT 
and RIT 
123I 13.2234 h ε (100%) 124Xe(p,2n)123Cs/123Xe/123I 
124Xe (p,pn)123I 
123Te(p,n)123I 
1228.6 Auger and 
CE 
RIT (Immuno-
SPECT) 
124I 4.1760 d ε+β+ (100%) 
β+ (22.7%) 
124Te(p,n)124I 3159.6 β+ 2137.6 Immuno-PET 
 
131I 8.0252 d β- (100%) 130Te(n,g)131Te/131I 970.8 β- 806.9  
Auger and CE 
RIT 
177Lu 6.647 d β- (100%) 176Lu(n,g)177Lu 
176Yb(n,g)177Yb/177Lu 
498.3 β- 498.3  
Auger and CE 
RIT (Immuno-
SPECT) 
213Bi 45.59 m α(2.20%) 
β-(97.80%) 
225Ac/213Bi β- 1423 
a 5988 
β- 1423 
a 5875 
Auger and CE 
RIT 
225Ac 10.0 d α(100%) 229Th/225Ra/225Ac 5935.1 a 5830 
Auger and CE 
RIT 
 
 
 
 
 
 
